

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) An isolated, synthetic or recombinant χ -conotoxin peptide comprising the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3

where Xaal is a ~~N-terminal~~ Xaal is a N-terminal pyroglutamate(pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion;

or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid and/or one or more amino acid residues other than Cys has undergone a side chain modification, or a salt, ester, amide or prodrug thereof.

2. (Currently amended) ~~An isolated, synthetic or recombinant χ -conotoxin~~ The peptide according to claim 1 consisting of the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3

where Xaal is a N-terminal pGlu or DpGlu residue; and Xaa2 is Asn or a deletion;

or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid and/or one or more amino acid residues other than Cys has undergone a side chain modification, or a salt, ester, amide or prodrug thereof.

3. (Currently amended) ~~[[A]]~~ The peptide according to claim 1 or 2 wherein ~~the~~ said sidechain ~~modifications are limited to the~~ comprises replacement of Tyr with 4-methoxy tyrosine and/or

replacement of Pro with 4-hydroxyproline.

4. (Currently amended) ~~An isolated, synthetic or recombinant χ -conotoxin~~ The peptide according to claim 1 having the following sequence of amino acids

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys	SEQ ID NO. 4
Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Xaa5	SEQ ID NO. 5
Xaal Gly Val Cys Cys Gly Xaa4 Lys Leu Cys His Xaa3 Cys	SEQ ID NO. 6
Xaal Asn Gly Val Cys Cys Gly Xaa4 Lys Leu Cys His Xaa3 Cys	SEQ ID NO. 7
Xaal Asn Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys	SEQ ID NO. 8
Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys-OH	SEQ ID NO. 9

where Xaal refers to pyroglutamic acid, Xaa3 refers to 4-hydroxyproline, Xaa4 refers to 4-methoxy tyrosine, Xaa5 refers to D-cysteine and-OH indicates a free acid C terminal.

5. (Currently amended) ~~An isolated, synthetic or recombinant χ -conotoxin~~ The peptide according to claim 1 having the following sequence of amino acids

Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys-OH	SEQ ID NO. 10
Xaal Gly Val Cys Cys Gly Tyr Lys Leu Cys His Xaa3 Cys	SEQ ID NO. 11

where Xaal refers to D-pyroglutamic acid, Xaa3 refers to 4-hydroxyproline and-OH indicates a free acid C terminal.

6. (Currently amended) A composition comprising ~~an isolated, synthetic or recombinant χ -conotoxin~~ the peptide of any one of claims 1 to 5 together with pharmaceutically acceptable carrier or diluent.
7. (Original) The composition of claim 6 further comprising one or more other active agents.
8. (Currently amended) Use of the χ -conotoxin ~~peptides~~ peptide of any one of claims 1 to 5 as ~~inhibitors~~ an inhibitor of neuronal noradrenaline transporter, and in the treatment or prophylaxis of diseases or conditions in relation to which the inhibition of neuronal noradrenaline transporter is associated with effective treatment.
9. (Original) Use according to claim 8 in the prophylaxis or treatment of diseases or conditions of the urinary or cardiovascular systems, or mood disorders, or in the treatment or control of acute, chronic and/or neuropathic pain, migraine or inflammation.
10. (Original) Use according to claim 9 in the treatment of neuropathic pain associated with surgery (post operative pain), gut, cancer, diabetic, phantom limb, nerve damage, inflammatory pain and peripheral nerve associated pain.
11. (Currently amended) A method for the treatment or prophylaxis of urinary or cardiovascular conditions or diseases or mood disorders or for the treatment or control of acute, chronic and/or neuropathic pain, migraine or inflammation ~~including the step of~~ comprising administering to a mammal an effective amount of an isolated, synthetic or recombinant χ -conotoxin peptide

having the ability to inhibit neuronal noradrenaline transporter, wherein said χ -conotoxin peptide comprises the following sequence of amino acids:

Xaal Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3

where Xaal is a N-terminal pGlu or DpGlu residue; and Xaa2 is Asn or a deletion;

or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid and/or one or more amino acid residues other than Cys has undergone a side chain modification, or a salt or prodrug thereof.

12. (Original) The method of claim 11 wherein the peptide is administered substantially simultaneously or sequentially with other agents useful in the treatment of the conditions, diseases or disorders.

13. (Currently amended) Use of ~~an isolated, synthetic or recombinant χ -conotoxin~~ the peptide of ~~any one of claims 1 to 5~~ claim 1 in the manufacture of a medicament for the treatment or prophylaxis of urinary or cardiovascular conditions or diseases, or mood disorders, or for the treatment or control of acute, chronic and/or neuropathic pain, migraine or inflammation.

14. (New) The method of claim 11 wherein said sidechain modification comprises replacement of Tyr with 4-methoxy tyrosine and/or replacement of Pro with 4-hydroxyproline.